Table 1 Characteristics of selected studies (n = 489) by funding: industry or non-industry
Characteristics | Industry funded (totally or partially) (n = 334) | Non-industry funded (n = 155) | Total (n = 489) | |
|---|---|---|---|---|
Registration | Before the start date of the study | 69 (20.7) | 43 (27.7) | 112 (22.9) |
| Â | Between the start date of the study and study primary completion date | 174 (52.1) | 58 (37.4) | 232 (47.4) |
| Â | After the study primary completion date | 91 (27.2) | 54 (34.8) | 145 (29.7) |
Medical field | Cardiovascular | 51 (15.3) | 27 (17.4) | 78 (16.0) |
| Â | Endocrinology | 61 (18.3) | 4 (2.6) | 65 (13.3) |
| Â | Infectious diseases | 46 (13.8) | 16 (10.3) | 62 (12.7) |
| Â | Urology/gynecology | 30 (9.0) | 13 (8.4) | 43 (8.8) |
| Â | Rheumatology | 23 (6.9) | 2 (1.3) | 25 (5.1) |
| Â | Bronchopulmonary | 20 (6.0) | 9 (5.8) | 29 (5.9) |
| Â | Neurology | 18 (5.4) | 6 (3.9) | 24 (4.9) |
| Â | Oncology | 12 (3.6) | 10 (6.5) | 22 (4.9) |
| Â | Gastroenterology | 11 (3.3) | 19 (12.3) | 30 (6.1) |
| Â | Ophthalmology | 10 (3.0) | 9 (5.8) | 19 (3.9) |
| Â | Psychiatry | 10 (3.0) | 2 (1.3) | 12 (2.5) |
| Â | Other | 42 (12.6) | 38 (24.5) | 80 (16.4) |
Location | Africa/Asia/South America | 114 (34.1) | 42 (27.1) | 156 (31.9) |
| Â | Europe/Australia/North America | 220 (65.9) | 113 (72.9) | 333 (68.1) |
Intervention | Drug | 278 (83.2) | 52 (33.5) | 330 (67.5) |
| Â | Device | 43 (12.9) | 45 (29.0) | 88 (18.0) |
| Â | Procedure/surgery | 9 (2.7) | 54 (34.8) | 63 (12.9) |
| Â | Other | 4 (1.2) | 4 (2.6) | 8 (1.6) |
Sample size | ≤100 | 68 (20.4) | 94 (60.6) | 162 (33.1) |
|  | 100–500 | 95 (28.4) | 40 (25.8) | 135 (27.6) |
| Â | >500 | 171 (51.2) | 21 (13.5) | 192 (39.3) |
Study objective | Safety or both safety and efficacy | 279 (83.5) | 72 (46.5) | 351 (71.8) |
Efficacy | 55 (16.5) | 83 (53.5) | 138 (28.2) | |